Hair Loss News

InterCytex has signed a licensing agreement with BioLife Solutions Inc., a leading developer and marketer of proprietary hypothermic storage and cryopreservation media products for cells and tissues.

Terms of the 10-year agreement include an intellectual property escrow provision which guarantees Intercytex access under certain conditions to BioLife’s HypoThermosol storage and preservation media when used in the production of Intercytex’ VAVELTA (ICX-RHY), a facial rejuvenation product and ICX-TRC, their hair regeneration product, as well as annual license fees payable to BioLife.

Intercytex Chief Executive Nick Higgins commented on the selection of BioLife’s technology and the licensing agreement: “We completed a thorough evaluation of several commercial and generic hypothermic storage and preservation media products. HypoThermosol clearly outperformed all competing alternatives, so securing long-term access to the product was a priority.”

BioLife Chief Executive Mike Rice stated: “We are extremely pleased to be providing Intercytex with key enabling technology for the commercialization of their new cell therapy products. As a growing number of companies have realized, when used as a transportation and preservation media for biologic source material and finished cell therapy products, HypoThermosol provides optimal post preservation cell viability and function. This agreement validates the diverse applications potential of our intellectual property portfolio and the benefits our products provide to the cell therapy market.

Intercytex is the leading cell therapy company focused on the restoration and regeneration of skin and hair. Intercytex is using its fully integrated cell technology platform to develop living, human cell-based products, at commercially viable scale in attractive markets. Intercytex commenced operations in 2000 and currently employs around 75 staff. In addition to its head office in Cambridge, UK, it has a GMP clinical production facility plus research and development laboratories in Manchester, UK. Additional laboratories are located in Boston, USA.